AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 611.74B +24.8% |
| Revenue (ttm) | 91.43B +10.4% |
| Net Income | 8.90B +67.7% |
| EPS | 5.03 +68.5% |
| Shares Out | n/a |
| PE Ratio | 68.70 |
| Forward PE | 16.47 |
| Dividend | 1.19 (3.42%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 616 |
| Open | 34.70 |
| Previous Close | 34.99 |
| Day's Range | 34.70 - 34.86 |
| 52-Week Range | 26.89 - 37.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission i...
AbbVie Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations with double-digit revenue growth and raised full-year guidance. Immunology and neuroscience segments drove performance, while the Apogee acquisition and new product approvals strengthen the long-term outlook.
AbbVie Earnings release: Q2 2026
AbbVie released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
AbbVie Quarterly report: Q2 2026
AbbVie has published its Q2 2026 quarterly earnings report on July 31, 2026.
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.
AbbVie cuts its full-year guidance to account for its pending acquisition of Apogee Therapeutics.
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.
AbbVie Reports Second-Quarter 2026 Financial Results
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0...
JUVÉDERM® Day Returns to U.S. on August 19
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. F...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whi...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas...
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may ...
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led ...
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon...
Buy these quality, low-stress stocks for the summer, says Jefferies
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more th...
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the...
US House committee opens investigation into Merck, AbbVie China drug trials
The chair of the U.S. House Select Committee on China opened national security investigations into whether five drugmakers including Merck and AbbVie have been involved in clinical trials conducted i...
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary ...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictabl...
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syri...
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens.